of T-cell proliferation occurs at an early stage following activation. This results in a failure of T-cells both to express receptors for IL-2 or to secrete IL-2 (Elliott et al.. 1984 : Prince & John. 1986 ). The effect is greater on cy.totoxic T-cells than on suppressor T-cells (Hess et al.. 1981) .
Inhibition by CsA of rodent and human leukaemic T-cell proliferation in vitro has been reported by a number of laboratories (Foa et al.. 1981 : Totterman et al.. 1982 & Adler. 1983 ) and clinical therapy of T-cell disease has been attempted (Puttick et al.. 1983 : Morland et al.. 1985 . There have also been reports of antiproliferative effects of CsA in tumour cells of non-T-cell origin, although these are generally observed at higher doses than found effective in T-cell studies. In two recent studies of the effect of CsA in hamster pancreatic and mouse colon cancer cell lines, it was found that the effects could be blocked by the addition of the polyamine. putrescine. and enhanced by the addition of the polyamine biosynthesis inhibitor a-difluoromethylorthinine (Saydjari et al.. 1986 (Saydjari et al.. . 1987 ).
An additional potential role for CsA in cancer therapy has recentlv been developed in that the compound has been found to act as an effective modifier of multidrug resistance (MDR) both in vitro and in vivo (Slater et al.. 1986 : Meador et al.. 1987 : Twentvman et al.. 1987 ). Addition of CsA to an agent such as adriamvcin or vincristine can. at least partially. restore sensitivity to cells in which MDR results from hyperexpression of P-glycoprotein. This property is also possessed bv some, but not all. analogues of CsA including nonimmunosuppressive analogues (Twentyman. 1988 : Chambers et al.. 1989 . Clinical trials of CsA as a resistance modifier are in progress (Sonneveld & Nooter. 1990 (Twentyman et al.. 1986 : Reeve et al.. 1989 ). This subline hyperexpresses P-glycoprotein and demonstrates an MDR drug accumulation deficit. The large cell lung carcinoma line COR-L23 P was derived in our laboratory (Baillie-Johnson et al.. 1985) and an MDR subline COR-L23 R obtained by growth in adriamycin (Twentyman et al.. 1986 (Twentyman et al.. 1986: Reeve et al.. 1990 and unpublished (Mosmann, 1983) as adapted im our laboratory for use with human lung cancer cell lines (Twentyman, 1988 Clonogenic cell survival assays were also carried out on cells exposed to cyclosporins for 4 or 24 h. Drugs were added in a small volume to 25 cm flasks of cells in the exponential phase of growth. At the end of the exposure period COR-L23 cells were rinsed three times in PBS and then reduced to a single cell suspension using a combination of trypsin and versene as previously described. Aggregates of small cell line COR-L88 were also dispersed for clonogenic assay using trYpsin versene. Following cell counting using haemocytometers. appropriate dilutions were made and survival was assayed using our previously described version (Walls & Twentyman. 1986 ) of the Courtenay and Mills (1978) soft agar assay. This assay uses incubation in low oxygen (5% O. 5% CO,. 90% air) and rat red blood cells as a source of nutrient to stimulate growth of clonogenic cells. Colonies containing more than 50 cells were counted after an incubation period of 3 weeks.
Polv amine determination Cells for polyamine assay were inoculated into 9 cm plastic petri dishes at numbers such that control cells would be in late exponential phase at the time of assay. 3 days later. Cyclosporins and or putrescine were added to the dishes 2 h after inoculation. At the time of assay. cells were washed twice with PBS and reduced to a single cell suspension using trypsin versene. Cells were resuspended in PBS. counted and polyamines were then extracted using 0.2 M perchloric acid as previously descnrbed (Wallace et al.. 1984) . The extracts were stored at -70°C and thawed immediately prior to polyamine assay. This was carried out by the hplc method of Wallace et al. (1988) . Results were corrected according to the previously determined cell numbers and expressed as nmoles l0' cells.
Results

Cell grow-th
Typical cell growth curves as determined using the MTT assay are shown in Figure 1 . In this example it is seen that. with increasing dose of either cyclosponrn, the effect increased from partial growth inhibition to complete growth inhibition to in situ cell destruction. In wells treated with 10 g ml-I Table  III . It may be seen that the effects were quite modest. Although significant effects were seen at 24 h. the reduction in cell survival was never more than 2-fold.
Effects ofputrescine
To test the hypothesis that growth inhibitory effects of cyclosporins may be due to polyamine depletion. the effect of adding exogenous putrescine was studied. In preliminary experiments with H69 P and COR-L88 cells it was found that. in a 6 day MTT assay. concentrations of putrescine up to 160gsgml-' (1 mM) had little if any effect on cell growth. We therefore tested the effect of adding a range of putrescine doses to either CsA or OACsA in the MTT assay. A typical data set for H69,P cells is shown in Figure 2 . There was clearly no protective effect produced by adding putrescine to either cyclosporin. Similar experiments with H69 LX4 and COR-L88 cells produced similar data and conclusions.
Effect of r-DMFO Preliminary experiments carried out with this compound in the MTT assay indicated that. at 0.1 mM. there was no effect on the growth of H69 P. COR-188 or COR-L23 P cells. At 0.2 and 0.5 mM there were detectable effects. the final optical densities being between 60 and 80% of control at 0.5 mM. The effect of combining ca-DMFO with CsA in COR-L88 is shown in Figure 3 . There was clearly no potentiation of the effect of CsA alone. Similar results were obtained in experiments with H69 P and COR-L23 P cells.
Polv amine levels
Data for the effects of cyclosporins on polyamine levels in COR-L23 and COR-L88 cells after 72 h treatment are shown in Tables IV and V. It may be seen that no reductions in polyamine levels resulted from any of these treatments.
Discussion
Antiproliferative and or cvtotoxic effects of CsA on human T cell leukaemia cells were reported by Foa et al. (1981) and by Totterman et al. (1982) . The effective doses of CsA in these studies were 5 and 0.1 tg mlP-I respectively with the drug being continuously present. A study by Yanagihara and Adler (1983) found that, in mouse lymphoreticular cell lines. treated continously with 5 jig ml1-CsA. a total loss of viability occurred in T-cell lines, whereas only a small degree of growth inhibition was seen in non-T cell lines. The first report of a possible antitumour activity for CsA was by Kreis and Sonrcelli (1979) . They found that repeated daily injections of the agent could inhibit the in vivo growth of a number of murine ascites tumours. These effects were obtained at doses close to the toxic limit. (>5ig ml-') for longer periods of time (>72 h), complete loss of cell viability occurs. In the clinical use of CsA as an immunosuppressive agent, a rapid initial phase of plasma clearance occurs following the attainment of peak levels of 1-2 jig ml-1 (Kahan et al., 1983) . Levels during the prolonged second plateau phase are very much lower (-0.1 jig ml-'). of polyamine synthesis. Saydjari et al. (1986 Saydjari et al. ( , 1987 (Saydjari et al., 1986) . In contrast to these data. McLachlan et al. (1991) Following a description of its ability to act as a modifier of multidrug resistance (Slater et al., 1986 : Twentyman et al.. 1987 CsA was shown to bind to P-glycoprotein. the putative drug efflux pump molecule involved in the MDR phenotype (Foxwell et al.. 1989) . It has also been demonstrated that MDR Chinese hamster cells accumulate less tritium-labelled CsA than the corresponding parent cells (Goldberg et al., 1988) . The clear reduction in CsA sensitivity seen in H69 LX4 (P-glycoprotein positive) compared with H69 P (Pglycoprotein negative) may therefore be accounted for by a similar differential CsA accumulation in this pair of cell lines. In our pairs of cell lines where the MDR phenotype occurs in the absence of P-glycoprotein. no such differential was seen.
The experiments which we have carried out do not clarify the mechanism whereby cyclosporins can inhibit cell growth. It is known that CsA binds to a specific cytosolic protein.
cyclophilin (Hardschumacher et al., 1984) and that this protein has peptidyl-prolyl cis-trans isomerase activity (Fischer et al.. 1989) . It has been recently suggested that such interactions may interfere with the activity of protein kinase C and cell signal transduction (Tropschug & Hoffman. 1991) . A number of groups have also reported effects of CsA on the physico-chemical properties of the plasma membrane. The drug binds to phospho-lipid vesicles, thereby disrupting membrane architecture (Haynes et al.. 1985) and interferes with the incorporation of fatty acids into the plasma membrane phospholipids of activated T-cells (Szamel et al.. 1986 ). It also depolarises cytoplasmic membrane potentials (Matyus et al.. 1986 ).
In conclusion. therefore. we have shown that CsA and OACsA will each inhibit growth of human lung cancer cells in *itro. but only at doses in excess of those which are clinically achievable. OACsA is. however, more potent than the parent compound and as further analogues enter clinical trial as possible resistance modifiers therefore. the possibility that antitumour effects of the cyclosporin alone may occur should be borne in mind.
